Novo Nordisk to Pay $6.3m to Resolve Allegations, US DOJ Says

Novo Nordisk agreed to pay $6.3m to resolve allegations that it violated the False Claims Act by selling items to the US that were manufactured in non-designated countries, the US Justice Department said.

• Settlement resolves claims that from July 2012 through November 2020, Novo Nordisk sold to US government agencies its NovoFine 30G 8mm needles, and that from May 2016 through November 2020, Novo Nordisk sold to US government agencies its NovoFine 32G 6mm needles, all of which were manufactured in non-designated countries
• Allegedly violated the Trade Agreements Act, which restricts procurement of goods under some government contracts to purchases ...